Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study
文献类型：期刊论文
| 作者 | Shen, Xia-Bo1,2; Li, Guang-Liang1,2; Zheng, Ya-Bing1,2; Chen, Zhan-Hong1,2; Cao, Wen-Ming1,2; Wang, Xiao-Jia1,2; Shao, Xi-Ying1,2 |
| 刊名 | ANNALS OF TRANSLATIONAL MEDICINE
 |
| 出版日期 | 2021-08-01 |
| 卷号 | 9 |
| 关键词 | Advanced breast cancer (ABC) aromatase inhibitors (AIs) everolimus (EVE) fulvestrant (FUL) retrospective study |
| ISSN号 | 2305-5839 |
| DOI | 10.21037/atm-21-3840 |
| 通讯作者 | Wang, Xiao-Jia(wxiaojia0803@163.com) ; Shao, Xi-Ying(shaoxy@zjcc.org.cn) |
| 英文摘要 | Background: Everolimus (EVE) is an inhibitor of the mammalian target of rapamycin (mTOR) pathway, and it is approved for the treatment of advanced breast cancer (ABC). However, there is still little real-world data on using EVE in Chinese breast cancer patients. We retrospectively analyzed real-world data to determine the factors affecting EVE treatment efficacy and patient outcomes. Methods: We retrospectively collected the treatment information of ABC patients treated with EVE from 2013 to 2020 in Zhejiang Cancer Hospital. Kaplan-Meier analysis and Cox regression methods were used to calculate and compare the progression-free survival (PFS), and identify the factors associated with EVE treatment efficacy. Results: The study finally enrolled 84 patients meeting the requirement; the median PFS in all 84 patients was 6.87 months. Multivariate analysis showed that liver metastasis [hazard ratio, 1.69; 95% confidence interval (CI), 1.00-2.84; P=0.049], and brain metastasis (hazard ratio, 2.65; 95% CI, 1.07-6.58; P=0.036) were independent risk factors. Subgroup analyses demonstrated EVE + fulvestrant (FUL) was not superior to EVE + aromatase inhibitors (AIs) for PFS (5.77 vs. 7.97 months, P=0.0735). Furthermore, it showed EVE + AI was superior to EVE + FUL in some subgroups: postmenopausal group (hazard ratio, 0.50; 95% CI, 0.26-0.98); without bone metastasis group (hazard ratio, 0.22; 95% CI, 0.06-0.80); visceral disease group (hazard ratio, 0.37; 95% CI, 0.20-0.69). Conclusions: EVE combined with endocrine therapy is an effective treatment option for Chinese patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) breast cancer, although EVE + FUL was not superior to EVE + AI. Liver metastasis and brain metastasis were independent risk factors for successful EVE + endocrine therapy. |
| WOS关键词 | PLUS EXEMESTANE ; AROMATASE INHIBITORS ; DOUBLE-BLIND ; FULVESTRANT ; MULTICENTER ; SAFETY |
| 资助项目 | Zhejiang Provincial Research Center for Cancer Intelligent Diagnosis and Molecular Technology[JBZX-202003] |
| WOS研究方向 | Oncology ; Research & Experimental Medicine |
| 语种 | 英语 |
| WOS记录号 | WOS:000687059100001 |
| 出版者 | AME PUBL CO |
| 资助机构 | Zhejiang Provincial Research Center for Cancer Intelligent Diagnosis and Molecular Technology |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/125155]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Wang, Xiao-Jia; Shao, Xi-Ying |
| 作者单位 | 1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Breast Med Oncol, Hangzhou 310022, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Shen, Xia-Bo,Li, Guang-Liang,Zheng, Ya-Bing,et al. Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study[J]. ANNALS OF TRANSLATIONAL MEDICINE,2021,9. |
| APA | Shen, Xia-Bo.,Li, Guang-Liang.,Zheng, Ya-Bing.,Chen, Zhan-Hong.,Cao, Wen-Ming.,...&Shao, Xi-Ying.(2021).Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study.ANNALS OF TRANSLATIONAL MEDICINE,9. |
| MLA | Shen, Xia-Bo,et al."Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study".ANNALS OF TRANSLATIONAL MEDICINE 9(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。